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ABSTRACT 
BACKGROUND 
 Diabetic neuropathy is a common complication that develops in 
nearly 50% of over all diabetes population especially long standing hyperglycemic 
patients. Diabetic neuropathy appears relatively early in the disease process. The 
prevalence of upto 7% is reported in South Indian patients even at the time of 
diagnosis of diabetes. Though precise mechanism of neuronal damage is unclear, 
accumulation of excess sorbitol through polyol pathway is supportive evidence. 
Recently Epalrestat and Methylcobalamin are widely used in clinical practice to 
manage diabetic neuropathy. This study was aimed to compare the efficacy and 
safety of Epalrestat with Methylcobalamin in patients with diabetic neuropathy. 
PATIENTS AND METHODS: 
 A total number of 165 patients with diabetic neuropathy were 
included in this study. The patients were divided into three groups; group A was 
administered with 150 mg of Epalrestat alone, group B was administered with 
1500 mcg of Methylcobalamin alone, Group C was administered with 150 mg of 
Epalrestat + 1500 mcg Methylcobalamin in combination once daily basis. The 
treatment period was 12 weeks with monitoring on week 4, 8 & 12 of the study. At 
base line and at follow up visits following parameters were evaluated: pain 
intensity by VAS pain score, loss of sensation, burning sensation, numbness, 
muscle cramps, spontaneous pain, weakness, dizziness, loss of sensation of heat & 
cold assessed by Michigan Neuropathy Screening Instrument score method 
(MNSI) & HbA1C. 
RESULTS: 
 All the parameters were improved in three groups compared to baseline 
screening. In group C significant (p<0.001) reduction in pain score (3.09) was 
observed at 8th week onwards while compared to baseline and very good reduction 
in pain score was observed at 12th week of therapy. All three groups had 
significant (p<0.001) reduction in MNSI score, especially group C were shown to 
have very good reduction compared to the rest other groups. With respect to 
HbA1C, both group A & C were shown equal amount (7.56%) of reductions 
compared to group B. 
CONCLUSION: 
  Combination of Epalrestat and Methylcobalamin was more efficacious, 
well tolerated and safer with safety for the management of diabetic neuropathy 
than monotherapy of Epalrestat and Methylcobalamin. The combination therapy 
showed better improvement of symptoms of Diabetic neuropathy 
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